Steven Basta serves as President and Chief Executive Officer of Phathom Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. With over two decades of experience in the pharmaceutical industry, particularly in gastroenterology, Basta has built a distinguished career leading commercial strategies for innovative therapies. He joined Phathom in 2020 as Chief Commercial Officer, playing a pivotal role in the company's transition to a commercial-stage entity, and ascended to President and CEO in 2021, guiding its growth amid the launch of its flagship product, VOQUEZNA (vonoprazan). Prior to Phathom, Basta spent more than a decade at Ironwood Pharmaceuticals, where he rose to Executive Vice President and Chief Commercial Officer. There, he spearheaded the successful commercialization of LINZESS (linaclotide), transforming it into a blockbuster therapy generating billions in annual sales through strategic partnerships with AbbVie and Takeda. His leadership drove market expansion, payer access, and physician adoption, solidifying Ironwood's position in the GI space. Earlier roles included key positions at Salix Pharmaceuticals, where he contributed to the launches of XIFAXAN (rifaximin) and other GI products, and at Prometheus Laboratories, focusing on diagnostic and therapeutic marketing. Under Basta's stewardship at Phathom, the company achieved FDA approval for VOQUEZNA in both erosive GERD and H. pylori infection regimens, marking a significant advancement in potassium-competitive acid blocker (P-CAB) therapy. His expertise in building high-performing teams and navigating complex regulatory and market landscapes has positioned Phathom for sustained growth, with ongoing efforts to expand VOQUEZNA's label and pipeline. Basta's track record of delivering commercial success underscores his commitment to addressing unmet needs in GI disorders.